Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Conduit Pharmaceuticals Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CDT
Nasdaq
2830
www.conduitpharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
- Feb 11th, 2025 2:00 pm
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
- Feb 7th, 2025 1:00 pm
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
- Jan 28th, 2025 10:30 am
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
- Jan 23rd, 2025 1:00 pm
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
- Jan 22nd, 2025 1:00 pm
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
- Dec 12th, 2024 12:30 pm
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
- Nov 21st, 2024 12:30 pm
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
- Nov 19th, 2024 9:30 pm
Conduit Pharmaceuticals announces new addition to autoimmune pipeline
- Nov 5th, 2024 12:40 pm
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
- Nov 4th, 2024 12:30 pm
Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
- Nov 1st, 2024 8:45 pm
Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Aug 28th, 2024 12:00 pm
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
- Aug 12th, 2024 11:00 am
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
- Aug 8th, 2024 10:30 am
Conduit Pharmaceuticals Granted Patent Approval For Autoimmune Diseases Treatment
- Jul 16th, 2024 6:52 pm
Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
- Jul 16th, 2024 11:30 am
Conduit Pharmaceuticals to Join Russell 3000® Index
- Jun 13th, 2024 12:00 pm
A Presidio Property Trust Major Investment To Be Part of Russell 2000®
- May 29th, 2024 8:21 pm
Conduit Pharmaceuticals Adds Key Leadership Positions
- Mar 19th, 2024 2:57 pm
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
- Mar 19th, 2024 11:00 am
Scroll